ALUR
Allurion Technologies Inc.
Medical - Devices
Market Cap$2M
5Y Perf.-99.7%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ALUR vs ELMD vs NVCR vs INGN
Revenue, margins, valuation, and 5-year total return — side by side.
ELMD
Electromed, Inc.
Medical - Devices
Market Cap$222M
5Y Perf.+154.8%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-87.3%
INGN
Inogen, Inc.
Medical - Devices
Market Cap$196M
5Y Perf.-86.3%
ALUR vs ELMD vs NVCR vs INGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ALUR | ELMD | NVCR | INGN |
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $2M | $222M | $1.92B | $196M |
| Revenue (TTM) | $17M | $69M | $674M | $351M |
| Net Income (TTM) | $-43M | $9M | $-173M | $-25M |
| Gross Margin | 61.0% | 78.2% | 75.2% | 47.6% |
| Operating Margin | -238.1% | 16.7% | -27.2% | -9.1% |
| Forward P/E | — | 24.4x | — | — |
| Total Debt | $38M | $198K | $290M | $17M |
| Cash & Equiv. | $15M | $15M | $103M | $104M |
ALUR vs ELMD vs NVCR vs INGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ALUR
ELMD
NVCR
INGN
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Allurion Technologi… (ALUR) | 100 | 0.3 | -99.7% |
| Electromed, Inc. (ELMD) | 100 | 254.8 | +154.8% |
| NovoCure Limited (NVCR) | 100 | 12.7 | -87.3% |
| Inogen, Inc. (INGN) | 100 | 13.7 | -86.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALUR vs ELMD vs NVCR vs INGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ELMD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Allurion Technologies Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ALUR
Allurion Technologies Inc.
The Income Pick
ALUR is the #2 pick in this set and the best alternative if income & stability is your priority.
- beta 0.82
- Beta 0.82 vs NVCR's 2.20
Best for: income & stability
ELMD
Electromed, Inc.
The Growth Play
ELMD carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 17.0%, EPS growth 48.3%, 3Y rev CAGR 15.4%
- 482.6% 10Y total return vs NVCR's 30.3%
- Lower volatility, beta 1.03, Low D/E 0.5%, current ratio 4.31x
- Beta 1.03, current ratio 4.31x
Best for: growth exposure and long-term compounding
NVCR
NovoCure Limited
The Specific-Use Pick
NVCR plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
INGN
Inogen, Inc.
The Secondary Option
INGN lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ELMD | 17.0% revenue growth vs ALUR's -39.9% |
| Quality / Margins | ELMD | 13.1% margin vs ALUR's -251.6% |
| Stability / Safety | ALUR | Beta 0.82 vs NVCR's 2.20 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ELMD | +22.1% vs ALUR's -71.4% |
| Efficiency (ROA) | ELMD | 16.4% ROA vs ALUR's -238.6% |
ALUR vs ELMD vs NVCR vs INGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
Segment breakdown not available.
Segment breakdown not available.
ALUR vs ELMD vs NVCR vs INGN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLELMDLAGGINGINGN
Who Leads Where
ELMD leads in 3 of 6 categories
ALUR leads 0 • NVCR leads 0 • INGN leads 0 • 2 tied
Explore the data ↓INGNInogen, Inc.
0leads
NVCRNovoCure Limited
0leads
ALURAllurion Technologies…
0leads
ELMDElectromed, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs ALURvs NVCRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ELMD5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ELMD7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ELMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ELMD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 39.2x ALUR's $17M. ELMD is the more profitable business, keeping 13.1% of every revenue dollar as net income compared to ALUR's -2.5%. On growth, ELMD holds the edge at +16.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ALURAllurion Technolo… | ELMDElectromed, Inc. | NVCRNovoCure Limited | INGNInogen, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $17M | $69M | $674M | $351M |
| EBITDAEarnings before interest/tax | -$40M | $12M | -$165M | -$16M |
| Net IncomeAfter-tax profit | -$43M | $9M | -$173M | -$25M |
| Free Cash FlowCash after capex | -$37M | $9M | -$48M | -$9M |
| Gross MarginGross profit ÷ Revenue | +61.0% | +78.2% | +75.2% | +47.6% |
| Operating MarginEBIT ÷ Revenue | -2.4% | +16.7% | -27.2% | -9.1% |
| Net MarginNet income ÷ Revenue | -2.5% | +13.1% | -25.7% | -7.1% |
| FCF MarginFCF ÷ Revenue | -2.1% | +13.4% | -7.1% | -2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -50.5% | +16.3% | +12.3% | +3.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.4% | +45.5% | -100.0% | -20.0% |
ELMD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ALUR and NVCR and INGN each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ALURAllurion Technolo… | ELMDElectromed, Inc. | NVCRNovoCure Limited | INGNInogen, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $2M | $222M | $1.9B | $196M |
| Enterprise ValueMkt cap + debt − cash | $24M | $207M | $2.1B | $110M |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | 31.23x | -13.80x | -8.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.42x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | 2.43x | — | — |
| EV / EBITDAEnterprise value multiple | — | 19.14x | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.05x | 3.47x | 2.92x | 0.56x |
| Price / BookPrice ÷ Book value/share | — | 5.42x | 5.51x | 1.02x |
| Price / FCFMarket cap ÷ FCF | — | 20.06x | — | — |
Evenly matched — ALUR and NVCR and INGN each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ELMD leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ELMD delivers a 19.8% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-51 for NVCR. ELMD carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ELMD scores 7/9 vs ALUR's 3/9, reflecting strong financial health.
| Metric | ALURAllurion Technolo… | ELMDElectromed, Inc. | NVCRNovoCure Limited | INGNInogen, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +19.8% | -50.8% | -12.9% |
| ROA (TTM)Return on assets | -2.4% | +16.4% | -16.5% | -8.3% |
| ROICReturn on invested capital | — | +25.6% | -16.4% | -24.4% |
| ROCEReturn on capital employed | -5.0% | +22.0% | -28.9% | -13.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.00x | 0.85x | 0.09x |
| Net DebtTotal debt minus cash | $23M | -$15M | $187M | -$86M |
| Cash & Equiv.Liquid assets | $15M | $15M | $103M | $104M |
| Total DebtShort + long-term debt | $38M | $198,000 | $290M | $17M |
| Interest CoverageEBIT ÷ Interest expense | -22.17x | — | -96.80x | — |
ELMD leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ELMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ELMD five years ago would be worth $27,805 today (with dividends reinvested), compared to $28 for ALUR. Over the past 12 months, ELMD leads with a +22.1% total return vs ALUR's -71.4%. The 3-year compound annual growth rate (CAGR) favors ELMD at 34.7% vs ALUR's -86.2% — a key indicator of consistent wealth creation.
| Metric | ALURAllurion Technolo… | ELMDElectromed, Inc. | NVCRNovoCure Limited | INGNInogen, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -53.1% | -1.9% | +28.3% | +8.4% |
| 1-Year ReturnPast 12 months | -71.4% | +22.1% | +1.1% | +0.3% |
| 3-Year ReturnCumulative with dividends | -99.7% | +144.6% | -75.7% | -39.3% |
| 5-Year ReturnCumulative with dividends | -99.7% | +178.1% | -91.3% | -89.2% |
| 10-Year ReturnCumulative with dividends | -99.7% | +482.6% | +30.3% | -85.3% |
| CAGR (3Y)Annualised 3-year return | -86.2% | +34.7% | -37.6% | -15.3% |
ELMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALUR and ELMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALUR is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ELMD currently trades 87.4% from its 52-week high vs ALUR's 19.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ALURAllurion Technolo… | ELMDElectromed, Inc. | NVCRNovoCure Limited | INGNInogen, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 1.03x | 2.20x | 1.10x |
| 52-Week HighHighest price in past year | $3.42 | $30.73 | $20.06 | $9.13 |
| 52-Week LowLowest price in past year | $0.26 | $17.73 | $9.82 | $5.34 |
| % of 52W HighCurrent price vs 52-week peak | +19.9% | +87.4% | +83.9% | +78.8% |
| RSI (14)Momentum oscillator 0–100 | 45.1 | 56.5 | 69.8 | 58.7 |
| Avg Volume (50D)Average daily shares traded | 194K | 41K | 1.5M | 282K |
Evenly matched — ALUR and ELMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ELMD as "Buy", NVCR as "Buy", INGN as "Buy". Consensus price targets imply 261.6% upside for INGN (target: $26) vs 41.5% for ELMD (target: $38).
| Metric | ALURAllurion Technolo… | ELMDElectromed, Inc. | NVCRNovoCure Limited | INGNInogen, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $38.00 | $33.50 | $26.00 |
| # AnalystsCovering analysts | — | 4 | 15 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.5% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ELMD leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallElectromed, Inc. (ELMD)Leads 3 of 6 categories
Loading custom metrics...
ALUR vs ELMD vs NVCR vs INGN: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ALUR or ELMD or NVCR or INGN a better buy right now?
For growth investors, Electromed, Inc.
(ELMD) is the stronger pick with 17. 0% revenue growth year-over-year, versus -39. 9% for Allurion Technologies Inc. (ALUR). Electromed, Inc. (ELMD) offers the better valuation at 31. 2x trailing P/E (24. 4x forward), making it the more compelling value choice. Analysts rate Electromed, Inc. (ELMD) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALUR or ELMD or NVCR or INGN?
Over the past 5 years, Electromed, Inc.
(ELMD) delivered a total return of +178. 1%, compared to -99. 7% for Allurion Technologies Inc. (ALUR). Over 10 years, the gap is even starker: ELMD returned +482. 6% versus ALUR's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALUR or ELMD or NVCR or INGN?
By beta (market sensitivity over 5 years), Allurion Technologies Inc.
(ALUR) is the lower-risk stock at 0. 82β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 170% more volatile than ALUR relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — ALUR or ELMD or NVCR or INGN?
By revenue growth (latest reported year), Electromed, Inc.
(ELMD) is pulling ahead at 17. 0% versus -39. 9% for Allurion Technologies Inc. (ALUR). On earnings-per-share growth, the picture is similar: Allurion Technologies Inc. grew EPS 79. 9% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, ELMD leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALUR or ELMD or NVCR or INGN?
Electromed, Inc.
(ELMD) is the more profitable company, earning 11. 8% net margin versus -81. 4% for Allurion Technologies Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELMD leads at 15. 1% versus -156. 3% for ALUR. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ALUR or ELMD or NVCR or INGN more undervalued right now?
Analyst consensus price targets imply the most upside for INGN: 261.
6% to $26. 00.
07Which pays a better dividend — ALUR or ELMD or NVCR or INGN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ALUR or ELMD or NVCR or INGN better for a retirement portfolio?
For long-horizon retirement investors, Electromed, Inc.
(ELMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +482. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELMD: +482. 6%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ALUR and ELMD and NVCR and INGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ALUR is a small-cap quality compounder stock; ELMD is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; INGN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ALUR: -50.5% · ELMD: 16.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.